Efficacy Study of Herbal Formula CUF2 to Treat Childhood Asthma
Primary Purpose
Asthma
Status
Completed
Phase
Phase 1
Locations
Hong Kong
Study Type
Interventional
Intervention
CUF2
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Asthma focused on measuring Traditional Chinese Medicine, Asthma, Paediatric
Eligibility Criteria
Inclusion Criteria:
- Persistent Mild to Moderate Asthma
- Aged 7 to 15 years
- On Regular inhaled steroid therapy
- Able to perform reproducible spirometry
Exclusion Criteria:
- Could not swallow capsules
- Received parenteral or oral corticosteroids, nedocromil, cromolyn, theophylline or anticonvulsants in past 4 weeks
Sites / Locations
- Department of Paediatrics, Prince of Wales Hospital
- Department of Paediatrics, Tuen Mun Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
CUF2
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Reduction of steroid dosage
Secondary Outcome Measures
Asthma symptoms
Lung function test
Biochemical markers
Full Information
NCT ID
NCT00636103
First Posted
March 11, 2008
Last Updated
March 11, 2008
Sponsor
Chinese University of Hong Kong
Collaborators
University Grants Committee, Hong Kong, Tuen Mun Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00636103
Brief Title
Efficacy Study of Herbal Formula CUF2 to Treat Childhood Asthma
Official Title
A Randomized Double-Blind Placebo-Controlled Study of the Effect of Traditional Chinese Medicines in the Treatment of Childhood Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
March 2008
Overall Recruitment Status
Completed
Study Start Date
July 2002 (undefined)
Primary Completion Date
August 2003 (Actual)
Study Completion Date
August 2003 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Chinese University of Hong Kong
Collaborators
University Grants Committee, Hong Kong, Tuen Mun Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Asthma is a long-term disease process with genetic, allergic, environmental, infectious, emotional and dietary influences. The symptoms control are mainly using an inhaled drug, avoiding triggers or taking preventive medicine. Although side effects are unlikely at low dose of the asthma treatment, they have become apparent at the higher dose. Due to safety concern, parents often turn to complementary and alternative medicine which they believe is natural and safe and may help to reduce the conventional medication dosage.
There are number of reports that treatment with traditional Chinese herbs or formulas resulted in significant improvement in lung function and reduction in the airway hyper-reactivity reaction. Our study drug CUF2, was based on a classical formulae and had been proven to have anti-inflammatory and immunomodulatory activities in laboratory and animal studies.
With the pre-clinical evidence, this study aims to determine the effect of CUF2 on improving the clinical symptoms, biochemical markers, and requirement of steroid dosage among children with asthma.
Detailed Description
Patients are recruited from 2 major governmental hospitals in Hong Kong (Prince of Wales Hospital and Tuen Mun Hospital),aged between 7 to 15 years with mild to moderate asthma according to the Global Initiative for Asthma guideline, on regular inhaled steroid therapy and capable to perform a lung function test.
However, those patients are excluded if they could not swallow capsules or had received parenteral or oral corticosteroids, nedocromil, cromolyn, theophylline or anticonvulsants in the past 4 weeks.
Before study start, written informed consent will be obtained from each patient and one of their parents. The eligible patients will be randomly assigned to receive CUF2 or placebo capsules for 6 months. For the dosage, children aged above 12 years old, 3 capsules twice daily and under 12 years old, 2 capsules twice daily.
During the 6 months period, below measurements will be taken:
The severity of asthma symptoms was assessed using a modified Disease Severity Score (DSS)
Lung Function Test by spirometry (SpiroPro Jaeger Toennies, Hoechberg, Germany)
Conventional Medication consumption, according to GINA/NIH guidelines.
Blood test, EDTA and clotted blood samples were taken at the baseline and end of the study for eosinophil counts, IgE level and cytokine assay.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Traditional Chinese Medicine, Asthma, Paediatric
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
90 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CUF2
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
CUF2
Intervention Description
0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).
The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.
Duration: 6 months
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Dark coloured corn starch
The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.
Duration: 6 months
Primary Outcome Measure Information:
Title
Reduction of steroid dosage
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Asthma symptoms
Time Frame
6 months
Title
Lung function test
Time Frame
6 months
Title
Biochemical markers
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
7 Years
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Persistent Mild to Moderate Asthma
Aged 7 to 15 years
On Regular inhaled steroid therapy
Able to perform reproducible spirometry
Exclusion Criteria:
Could not swallow capsules
Received parenteral or oral corticosteroids, nedocromil, cromolyn, theophylline or anticonvulsants in past 4 weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rita YT Sung, MD
Organizational Affiliation
Chinese University of Hong Kong
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Paediatrics, Prince of Wales Hospital
City
Hong Kong
Country
Hong Kong
Facility Name
Department of Paediatrics, Tuen Mun Hospital
City
Hong Kong
Country
Hong Kong
12. IPD Sharing Statement
Citations:
PubMed Identifier
9042632
Citation
Leung R, Wong G, Lau J, Ho A, Chan JK, Choy D, Douglass C, Lai CK. Prevalence of asthma and allergy in Hong Kong schoolchildren: an ISAAC study. Eur Respir J. 1997 Feb;10(2):354-60. doi: 10.1183/09031936.97.10020354.
Results Reference
background
PubMed Identifier
9568941
Citation
Lau YL, Karlberg J. Prevalence and risk factors of childhood asthma, rhinitis and eczema in Hong Kong. J Paediatr Child Health. 1998 Feb;34(1):47-52. doi: 10.1046/j.1440-1754.1998.00217.x.
Results Reference
background
PubMed Identifier
10836329
Citation
Rao R, Gregson RK, Jones AC, Miles EA, Campbell MJ, Warner JO. Systemic effects of inhaled corticosteroids on growth and bone turnover in childhood asthma: a comparison of fluticasone with beclomethasone. Eur Respir J. 1999 Jan;13(1):87-94. doi: 10.1183/09031936.99.13108799.
Results Reference
background
PubMed Identifier
8932956
Citation
But P, Chang C. Chinese herbal medicine in the treatment of asthma and allergies. Clin Rev Allergy Immunol. 1996 Fall;14(3):253-69. doi: 10.1007/BF02802218. No abstract available.
Results Reference
background
PubMed Identifier
9116877
Citation
Hsieh KH. Evaluation of efficacy of traditional Chinese medicines in the treatment of childhood bronchial asthma: clinical trial, immunological tests and animal study. Taiwan Asthma Study Group. Pediatr Allergy Immunol. 1996 Aug;7(3):130-40. doi: 10.1111/j.1399-3038.1996.tb00120.x.
Results Reference
background
PubMed Identifier
10806598
Citation
Critchley JA, Zhang Y, Suthisisang CC, Chan TY, Tomlinson B. Alternative therapies and medical science: designing clinical trials of alternative/complementary medicines--is evidence-based traditional Chinese medicine attainable? J Clin Pharmacol. 2000 May;40(5):462-7. doi: 10.1177/00912700022009224.
Results Reference
background
PubMed Identifier
10823504
Citation
Lin LZ, He XG, Lindenmaier M, Nolan G, Yang J, Cleary M, Qiu SX, Cordell GA. Liquid chromatography-electrospray ionization mass spectrometry study of the flavonoids of the roots of Astragalus mongholicus and A. membranaceus. J Chromatogr A. 2000 Apr 21;876(1-2):87-95. doi: 10.1016/s0021-9673(00)00149-7.
Results Reference
background
PubMed Identifier
10812678
Citation
Patocka J. Anti-inflammatory triterpenoids from mysterious mushroom Ganoderma lucidum and their potential possibility in modern medicine. Acta Medica (Hradec Kralove). 1999;42(4):123-5.
Results Reference
background
PubMed Identifier
10549581
Citation
Cheong J, Jung W, Park W. Characterization of an alkali-extracted peptidoglycan from Korean Ganoderma lucidum. Arch Pharm Res. 1999 Oct;22(5):515-9. doi: 10.1007/BF02979162.
Results Reference
background
PubMed Identifier
8503668
Citation
Kong XT, Fang HT, Jiang GQ, Zhai SZ, O'Connell DL, Brewster DR. Treatment of acute bronchiolitis with Chinese herbs. Arch Dis Child. 1993 Apr;68(4):468-71. doi: 10.1136/adc.68.4.468.
Results Reference
background
PubMed Identifier
3605835
Citation
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis. 1987 Jul;136(1):225-44. doi: 10.1164/ajrccm/136.1.225.
Results Reference
background
PubMed Identifier
19821718
Citation
Wong EL, Sung RY, Leung TF, Wong YO, Li AM, Cheung KL, Wong CK, Fok TF, Leung PC. Randomized, double-blind, placebo-controlled trial of herbal therapy for children with asthma. J Altern Complement Med. 2009 Oct;15(10):1091-7. doi: 10.1089/acm.2008.0626.
Results Reference
derived
Learn more about this trial
Efficacy Study of Herbal Formula CUF2 to Treat Childhood Asthma
We'll reach out to this number within 24 hrs